✦ LIBER ✦

The OCT drug review — FDA's viewpoint

✍ Scribed by W. E. Gilbertson

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Innovation and the FDA: A Clinician's Vi

✍ JAMES D. MALONEY 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 247 KB

Drug Development and the FDA's Critical

✍ Woosley, R L; Cossman, J 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 146 KB

An Outsider’s Viewpoint: The FDA Should

✍ O’Kane, D 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 131 KB

Drug Development for Neglected Diseases

✍ Kesselheim, Aaron S. 📂 Article 📅 2008 🏛 Massachusetts Medical Society 🌐 English ⚖ 99 KB

Report slams US FDA's drug safety reform

✍ Nellie Bristol 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 33 KB

Stereoisomeric Drugs: FDA'S Policy State

✍ Tomaszewski, John; Rumore, Martha M. 📂 Article 📅 1994 🏛 Informa plc 🌐 English ⚖ 838 KB